Raffles Medical GroupSGX:BSL +0.54%82 Cash-to-Debt is 3.56 as of Dec. 2025, which is 79% above its 10-year median of 1.99. GuruFocus rates SGX:BSL with a GF Score™ of 82/100 and a GF Value™ of S$1.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Raffles Medical Group ranks better than 71.49% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Raffles Medical Group's cash to debt ratio for the quarter that ended in Dec. 2025 was 3.56.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Raffles Medical Groupcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Raffles Medical Group's Cash-to-Debt or its related term are showing as below:
SGX:BSL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.76 Med: 1.99 Max: 3.9
Current: 3.56
During the past 13 years, Raffles Medical Group's highest Cash to Debt Ratio was 3.90. The lowest was 0.76. And the median was 1.99.
SGX:BSL's Cash-to-Debt is ranked better than 71.49% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.76
vs SGX:BSL: 3.56
Raffles Medical Group (SGX:BSL) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Raffles Medical Group Cash-to-Debt Related Terms
Raffles Medical Group Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Raffles Medical Group's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Care Facilities subindustry, Raffles Medical Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raffles Medical Group Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raffles Medical Group's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Raffles Medical Group's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raffles Medical Group (SGX:BSL) has a Cash-to-Debt of 3.56 as of Dec. 2025. This is 79% above median its historical median of 1.99. Over the past decade, Raffles Medical Group's Cash-to-Debt has ranged from 0.76 to 3.90. According to the industry distribution chart, Raffles Medical Group ranks #191 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 28.5%.
Is Raffles Medical Group's Cash-to-Debt too high?
Raffles Medical Group's current Cash-to-Debt of 3.56 is 79% above median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 3.90. The Healthcare Providers & Services industry median Cash-to-Debt is 0.76. Raffles Medical Group's value of 3.56 is 368.4% above this industry median. Based on the distribution chart, Raffles Medical Group ranks #191 out of 670 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raffles Medical Group has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raffles Medical Group's Cash-to-Debt compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Raffles Medical Group ranks #191 out of 670 companies for Cash-to-Debt. This puts Raffles Medical Group in the upper half of its industry. The industry median Cash-to-Debt is 0.76. Raffles Medical Group's value of 3.56 is 368.4% above this benchmark. Historically, Raffles Medical Group's own Cash-to-Debt has ranged from 0.76 to 3.90 over the past decade. While the company's 10-year median is 1.99 vs. the industry median of 0.76, Raffles Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.76, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raffles Medical Group's current Cash-to-Debt of 3.56 is 368.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raffles Medical Group's current Cash-to-Debt is 3.56, which is 79% above median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raffles Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Raffles Medical Group (SGX:BSL) is currently considered Modestly Undervalued. The stock's GF Value™ is S$1.05, compared to a current price of S$0.93 — trading 11.9% below its estimated fair value. The current Cash-to-Debt is 3.56, which is 79% above median its 10-year median of 1.99 and 368.4% above the Healthcare Providers & Services industry median of 0.76. Raffles Medical Group's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Raffles Medical Group (SGX:BSL), the current Cash-to-Debt is 3.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raffles Medical Group (SGX:BSL) Overvalued in 2026?
Based on GuruFocus' analysis, Raffles Medical Group stock appears to be undervalued.
The current stock price of S$0.93 is trading 11.9% below its estimated GF Value™ of S$1.05.
GuruFocus considers Raffles Medical Group to be Modestly Undervalued.
Key valuation signals for SGX:BSL:
Cash-to-Debt: 3.56 (79% above median its 10-year median of 1.99)
GF Value™: S$1.05 vs. price of S$0.93 (11.9% below fair value)
Industry Position: 368.4% above the Healthcare Providers & Services median (#191 of 670)
No single metric tells the full story. See the SGX:BSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raffles Medical Group Ltd is an integrated private healthcare provider in Asia with operations in Singapore, China, Japan, Vietnam, and Cambodia. The company owns and operates a tertiary hospital, a network of medical and dental clinics, insurance services, Japanese and Traditional Chinese Medicine clinics, and a consumer healthcare division. The company's operating segment includes Healthcare services, Hospital Services, Investment Holdings, and Insurance Services. The company generates revenue from contracts with customers, Rental Income, and Insurance revenue. Geographically operates in Singapore, Greater China, Vietnam, Cambodia and Japan.
82GF Score
Get the complete analysis for SGX:BSL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BSL has been successfully added to your 
